Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

de extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

Cephalon Europe

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four therapeutic areas: central nervous system, pain, primary care and oncology.

Among its oncology products, Cephalon Europe markets MYOCET(R) (liposomal doxorubicin) which is indicated in combination with cyclophospamide for first- line treatment of metastatic breast cancer; TARGRETIN(R) (bexarotene) for advanced cutaneous T-cell lymphoma; and TRISENOX for relapsed or refractory acute promyelocytic leukemia.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products, including with respect to EFFENTORA; sales, adjusted net income and basic adjusted income per common share guidance;
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... Pittcon is pleased to announce that the ... Horiba Scientific, have organized a session on nanotechnology for ... , Asia’s largest analytical and scientific instruments show, will ... , The four speakers in this U.S. symposium, ... to Single Cells” will present their use of nanotechnology ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in ... industry, is asking industry professionals to prepare for fall ... E2 soap they’re currently using to the Best Sanitizers’ ... Hand hygiene is critical to fighting cross-contamination and the ... key criteria are identified to evaluate the effectiveness of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... April 25 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... May 1, 2008, after market close., The announcement ... by a conference call and live webcast on May ... Interested parties may access the live,call by dialing 888.680.0878 ...
... and Collaborators Publish Study in Science, ... GmbH, the,leading developer of RAFT intervention therapeutics, ... Science demonstrating a potential novel strategy,for therapeutic ... targeting,discrete sub-compartments in the cell membrane (RAFTS). ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on May 1, 2008 at,approximately 4:20 p.m. Eastern ... may be accessed through a link on the investors ... will be,available for 30 days following the event., ...
Cached Biology Technology:Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:8/29/2014)... and number of connections in transcription factor networks (TFNs) ... a study published in PLOS Computational Biology ... signature contributes to a network,s resilience against mutations. ... assortativity of TFN models has a greater effect on ... of assortativity," said Dov A. Pechenick, PhD, lead author ...
(Date:8/29/2014)... in German . ... is considered the oldest form of communication. Acting as ... example, the sexual attraction between males and females. Fish ... coordinate reproductive behavior in males and females. Scientists at ... Algarve in Faro, Portugal, and at the Max Planck ...
(Date:8/29/2014)... a cell,s nucleus, chromosomal DNA is tightly bound ... biologists call chromatin. Until about two decades ago, ... mere packing material around which the glamorous DNA ... a greater appreciation for how DNA/histone interactions govern ... research institutions studying the sequence of the genome ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... 25, 2013) A team of researchers at The ... Scott Noggle, PhD, Director of the NYSCF Laboratory and ... Alzheimer,s Disease, and Michael W. Nestor, PhD, a NYSCF ... three-dimensional cultures of induced pluripotent stem (iPS) cells called ...
... California sagebrush in the southern part of the ... populations in the north, according to UC Irvine researchers ... with the Center for Environmental Biology. The results ... Change Biology , will assist land management and policy ...
... 2013 Listed below are the selected highlights for the ... Genetics . The April issue is available online ... Vol. 193, April 2013, Copyright 2013. Please feel ... these articles on a wide array of topics including methods, ...
Cached Biology News:NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimer's disease 2Southern California sagebrush better suited to climate change, UCI study finds 2Genetics Society of America's Genetics journal highlights for April 2013 2Genetics Society of America's Genetics journal highlights for April 2013 3Genetics Society of America's Genetics journal highlights for April 2013 4
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Biology Products: